Farudodstat
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01992367)
Timeline
Indications
Mechanism of action
- Dihydroorotate dehydrogenaseINHIBITOR
DHODH inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC1=CC=CC(=C1)C2=CC(F)=C(NC3=C(C=CC=N3)C(O)=O)C(F)=C2- Mol. weight
- 356.3229 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSI58WE41H6X ↗
- ChEMBLCHEMBL2263632 ↗
Also known as
- aslan003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05865041 | Phase 2 | Apr 14, 2023 | Aslan Pharmaceuticals |
| NCT03451084 | Phase 2 | Jan 5, 2018 | Aslan Pharmaceuticals |
| NCT02342652 | Phase 1 | Oct 1, 2014 | Aslan Pharmaceuticals |
| NCT01992367 | Phase 1 | Aug 1, 2013 | Aslan Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aslan Pharmaceuticals | For profit | 4 | 4 | 2 | 2013 |
1 organizations
Page 1 / 1